Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: conix, Foxwoods Man, drkazmd65, The_Q, Charmed7713, Dudmuffin
Search This Board: 
Last Post: 3/28/2020 3:28:01 AM - Followers: 290 - Board type: Free - Posts Today: 1

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4








Products In Development

 

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.

https://www.prnewswire.com/news-releases/biotech-brief-growing-number-of-ongoing-clinical-trials-for-leukemia-aml-brings-new-hope-300827745.html

http://KillCVMShorts.com/faqs

http://KillCVMShorts.com/idmc

http://KillCVMShorts.com

http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

https://seekingalpha.com/instablog/50299941-cvm4life/5309598-setting-record-straight-cel-sci

https://seekingalpha.com/article/4275913-cel-sci-verge-approval#alt2

CVM shares held by iHub investors :

https://docs.google.com/spreadsheets/d/1aU3buYiKiQZDyNPRIBZWGoUk37TrlSjJ/edit#gid=1952396312

https://seekingalpha.com/article/4275913-cel-sci-verge-approval#alt2














 

CVM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM News: Securities Registration Statement (s-1/a) 02/20/2020 05:19:02 PM
CVM News: Withdrawal of Registration Statement (ammendment) (aw) 02/20/2020 04:42:10 PM
CVM News: Current Report Filing (8-k) 02/20/2020 12:08:11 PM
CVM News: CEL-SCI Corporation Reports First Quarter Fiscal 2020 Financial Results 02/10/2020 08:00:00 AM
CVM News: Quarterly Report (10-q) 02/10/2020 06:49:47 AM
PostSubject
#19754  Sticky Note Welcome CVM Newbies sushifishman 04/06/19 08:25:19 AM
#30259   Has anyone heard from Parker? Charmed7713 03/28/20 03:28:01 AM
#30258   New ownership listings: Fidelity with almost 150,000 shares And Schwab trickledownfacists 03/27/20 07:08:56 PM
#30257   @Biobonic Thanks very much for that info, to be sab63090 03/27/20 05:23:17 PM
#30256   China is rioting because they want to go trickledownfacists 03/27/20 04:37:19 PM
#30255   What is occurring there is the delay or Biobonic 03/27/20 04:36:10 PM
#30254   Very good day for virus data maturity lightrock 03/27/20 04:31:48 PM
#30253   Sure hope this doesn’t cause any delays for hogg 03/27/20 03:40:24 PM
#30252   @Fox Currently 293 cases per 1 million population lightrock 03/27/20 03:35:48 PM
#30251   Jeez, another example of greed over compassion...what a shame... RobotDroid 03/27/20 03:33:10 PM
#30250   @Bio THX, interesting... I am adding it to the lightrock 03/27/20 03:26:49 PM
#30249   Well there is this Biobonic 03/27/20 03:19:25 PM
#30248   I'm just glad that this pandemic did't occur Foxwoods Man 03/27/20 03:17:57 PM
#30247   @george Well, 1.3 billion is a lot of people lightrock 03/27/20 03:09:02 PM
#30246   @Lrock I have to say "sort of maybe kinda"--LOL. georgebailey 03/27/20 02:53:17 PM
#30245   I have to say "sort of maybe kinda" lightrock 03/27/20 02:42:40 PM
#30244   Lrock, Is China's data unreliable in your opinion? georgebailey 03/27/20 02:34:23 PM
#30243   @george There are limits to how "wrong" China data lightrock 03/27/20 02:21:28 PM
#30242   Lightrock why do we think that China's data georgebailey 03/27/20 02:17:13 PM
#30241   @sab The news in the next 2-3 weeks is lightrock 03/27/20 02:06:58 PM
#30240   Agreed trickledownfacists 03/27/20 11:07:15 AM
#30239   @Mogles Good point about the likelihood of COVID-19 forcing sab63090 03/27/20 11:04:55 AM
#30238   I'm sure everyone who is barely surviving a The_Q 03/27/20 11:02:06 AM
#30237   every horse we talk about here, is not The_Q 03/27/20 11:00:13 AM
#30236   From that posted conversation with Gavin, sounds like RobotDroid 03/27/20 10:59:38 AM
#30235   If 298 has not been achieved yet, Covid19 Mogles 03/27/20 10:26:59 AM
#30234   Maybe this has already been discussed, but I thinkingonlygreen 03/27/20 09:56:01 AM
#30233   I like that thought....a lot Foxwoods Man 03/27/20 08:25:04 AM
#30232   Ah, VERY interesting, Trickle. Nice one. Chuckster1 03/27/20 04:53:22 AM
#30231   Posted elsewhere: "I had a nice conversation with Gavin trickledownfacists 03/26/20 07:36:58 PM
#30230   Not to beat a dead horse, but... lightrock 03/26/20 06:18:32 PM
#30229   They also got a contract from an Italian Mogles 03/26/20 04:06:41 PM
#30228   https://news.yahoo.com/us-virus-deaths-may-top-80-000-despite-161924116.html RobotDroid 03/26/20 03:40:43 PM
#30227   Ergomed upgraded from ADD to BUY at Numis. ER18 03/26/20 03:39:35 PM
#30226   We are also mentioned here, about 3/4 thru it...https://www.clinicaltrialsarena.com/analysis/coronav RobotDroid 03/26/20 02:15:55 PM
#30225   https://www.drugtargetreview.com/news/58326/collaboration-initiated-to-develop-covid-19-immunotherap RobotDroid 03/26/20 02:06:32 PM
#30224   Why was the shareholder meeting moved up to greens12 03/26/20 12:45:00 PM
#30223   Trickle Yes nice cash receipt with another 1M georgebailey 03/26/20 11:40:09 AM
#30222   Offering has closed. $7.7M cash trickledownfacists 03/26/20 11:38:02 AM
#30221   One thing worth repeating lightrock 03/26/20 11:34:24 AM
#30220   That doesn't matter, once the data is mature lightrock 03/26/20 11:10:09 AM
#30219   It will not even peak by then. One RobotDroid 03/26/20 11:08:51 AM
#30218   A solid picture should emerge in about 7-14 days. lightrock 03/26/20 10:52:27 AM
#30217   My backyard was 80 miles from Dorian, which Trickshot 03/26/20 10:32:09 AM
#30216   I am amazed by the number of people RobotDroid 03/26/20 09:31:51 AM
#30215   Interesting NY Times links lightrock 03/26/20 07:30:37 AM
#30214   What took Adam F so long to diss $CVM? sab63090 03/26/20 06:35:20 AM
#30213   agree, looking forward to Data...that is all that greens12 03/25/20 08:48:58 PM
#30212   With the current global condition, I believe LEAPS trickledownfacists 03/25/20 08:37:56 PM
#30211   Greens....he often does that. Calls people stupid rizona 03/25/20 07:55:09 PM
#30210   There was a PI set up at Johns bluepelican 03/25/20 07:44:41 PM
PostSubject